Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 8:13 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1993–2016 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Newly Diagnosed Multiple Myeloma
Interventions: Isatuximab, Iberdomide, Bortezomib, Dexamethesone; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Cryptoglandular Perianal Fistula
Interventions: E-CEL UVEC Cells; Biological
Lead sponsor: Angiocrine Bioscience; Industry
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Cutaneous Melanoma, Stage II, Cutaneous Melanoma, Acral Melanoma
Interventions: Wide Local Excision; Diagnostic Test
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: MelanomaCutaneous Melanoma Resectable, Melanoma
Interventions: RP2 (vusolimogene oderparepvec), Nivolumab, Definitive Surgical Resection; Drug · Procedure
Lead sponsor: Yana Najjar; Other
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: ePRO, Symptom Monitoring, Neoadjuvant Therapy, Pancreatic Adenocarcinoma, Clinical Outcomes
Interventions: Standard of Care; Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cannabis Use Disorder, Major Depressive Disorder (MDD)
Interventions: Pregnenolone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Dallas, Texas • Richardson, Texas

Conditions: Emotional Distress
Interventions: Mystics Pet; Device
Lead sponsor: Stanford University; Other
Eligibility: 4 Years to 17 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Common Warts, Common Warts (Verruca Vulgaris), Human Papilloma Virus (HPV), Warts
Interventions: VP-102; Combination Product
Lead sponsor: Verrica Pharmaceuticals Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Bowling Green, Kentucky • Owensboro, Kentucky • New York, New York + 1 more

Conditions: Substance Use Disorder (SUD)
Interventions: CourtConnect, Information Only; Behavioral · Other
Lead sponsor: RTI International; Other
Eligibility: 18 Years to 100 Years
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: South Bend, Indiana • Research Triangle Park, North Carolina

Conditions: Healthy Volunteers, Sympathetic Activity
Interventions: Lidocaine 2%; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Epigenetic Aging
Interventions: Switch from an ART regimen containing lamivudine (3TC) or emtricitabine (FTC) + tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) to DOR/ISL, Switch from an nucleoside reverse transcriptase inhibitor (NRTI)-sparing ART regimen containing greater than or equal to 2 drugs to DOR/ISL, Continue SoC ART; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 35 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: Aurora, Colorado • Houston, Texas

Conditions: Lumbar Fusion Surgery
Interventions: Intraosseous Vancomycin, Intravenous Vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cachexia-Anorexia Syndrome
Interventions: Selpercatinib, Strength Assessment; Drug · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cataract Surgery, Eye Care, Glasses, Primary Eye Care, Vision Center, Eyecare Visits
Interventions: Establishment of a vision center; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: Not listed
Enrollment: 150,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Infra-orbital Hollows, Skin Quality Improvement
Interventions: RhPDGF-BB, Normal Saline; Biological · Drug
Lead sponsor: Lynch Regenerative Medicine; Network
Eligibility: 21 Years to 65 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 6
States / cities: Newport Beach, California • Santa Monica, California • Chicago, Illinois + 3 more

Conditions: Physical Activity, Fitness Tracker, Behavioral Intervention, Primary Care
Interventions: Physical Activity Counseling Tool (PACT); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Chronic Insomnia
Interventions: Low Dose Drug A, Low Dose Drug B, High Dose Drug A, High Dose Drug B, SOM001-A, SOM001-B, SOM001-C, SOM001-D, Placebo; Drug
Lead sponsor: Somnum Pharma Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Inflammatory Response Syndrome
Interventions: Not listed
Lead sponsor: Akron Children's Hospital; Other
Eligibility: 1 Day to 5 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Pain, Acute, Anxiety Acute
Interventions: Mindfulness + Meaning Making Questions, Mindfulness + Implementation Questions; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Upper Gastrointestinal Discomfort
Interventions: Mānuka Honey Active Product 1, Mānuka Honey Active Product 2, Placebo Control; Other
Lead sponsor: Radicle Science; Industry
Eligibility: 21 Years to 105 Years
Enrollment: 775 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Del Mar, California

Conditions: Defibrillator, Tricuspid Valve Regurgitation
Interventions: Defibrillator; Device
Lead sponsor: Minneapolis Heart Institute Foundation; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Repetitive Negative Thinking, Serious Mental Illness Symptoms
Interventions: Mindfulness Training, Active mindfulness-based neurofeedback (Active mbNF), Sham mindfulness-based neurofeedback; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 14 Years to 21 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Autism, Autism Spectrum Disorder
Interventions: MapHabit System (MHS); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 24 Years
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Chronic Pain
Interventions: EpiFaith™ Syringe, Conventional Loss-of-Resistance Syringe; Device
Lead sponsor: Flat Medical Co., Ltd; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 2
States / cities: San Diego, California • Temecula, California

Search by objective public record fields.

Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

E-CEL UVEC Cell Injection Treatment of Perianal Fistulas

Trial Comparing CPDMA Versus Standard Breadloafing in WLE Specimens of Stage 1-II Cutaneous Melanoma

Neoadjuvant RP2 + Nivolumab in Patients With Melanoma

Impact of Routine Electronic Patient-Reported Outcome (ePRO)Symptom Monitoring During Neoadjuvant Therapy in Patients withPancreatic Adenocarcinoma on Patient Experience and ClinicalOutcomes: A Prospective Pre-Post Implementation Study

Pregnenolone for Cannabis Use Disorder and Depression

A Novel Auditory Application for Distraction in Pediatric Patients

Safety and Systemic Exposure of YCANTH (VP-102) in Subjects With Common Warts (Verruca Vulgaris) (COVE-5)

Preventing Overdose and Promoting Recovery Through Court Navigation

SPARK Study - Sympathetic Periarterial Radial Block in Healthy Volunteers

Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV

IO Vancomycin Spine

Feasibility Study for Repurposing RET Inhibitors

Effect of Vision Centers on Access to Eye Care and Eye Health Outcomes

Phase 2 Evaluation of Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) Injection for the Treatment of Infraorbital Hollowing

Guided Physical Activity Counseling: A Pilot Study

A Study of Oral SOM001 as a Safe and Effective Treatment for Adults With Chronic Insomnia

Conventional Ultrafiltration Versus Dilutional Ultrafiltration in Pediatric CPB Patients

Brief Postoperative Pain Management Intervention: Meaning Making Amendment

Impact of Lepteridine™ Mānuka Honey in Adults With Gastrointestinal Discomfort

Early Feasibility Study of 3930M Defibrillation Lead Implantation Via the Middle Cardiac Vein in Patients With Tricuspid Valve Regurgitation

Mindfulness-based Neurofeedback to Reduce Negative Thinking in CHARMS Adolescents

Evaluating the Feasibility of Collecting User Interaction Data at the Emory Autism Center Using MapHabit Software

Clinical Evaluation of the EpiFaith™ Syringe in Epidural Pain Management